Lithuanian Startup Vugene Secures €1M to Advance Multi-Omics Research

Team S · 2025-05-06T16:29:47.000Z

Vugene, a Lithuanian startup specializing in multi-omics data analysis, has raised €1 million in a seed funding round led by Superhero Capital, with participation from ScaleWolf and angel investors including Darius Žurauskas, Donatas Karčiauskas, and Gytis Labašauskas. The company aims to transform complex biological data into actionable insights for researchers tackling global health challenges such as cancer, neurodegenerative diseases, and rare disorders. Vugene leverages advanced AI and machine learning to streamline the analysis of multi-omics data—encompassing genomics, proteomics, and metabolomics. Its platform empowers academic institutions, biotech firms, and pharmaceutical companies to accelerate drug discovery and develop precision medicine solutions. With a €16 billion addressable market, Vugene addresses a critical bottleneck in life sciences research, where the volume and complexity of biological data often outpace analytical capabilities. “Vugene’s team is unlocking the potential of multi-omics to drive breakthroughs in healthcare,” said Juha Lindfors, Managing Partner at Superhero Capital. “This funding will enable them to scale their platform and expand their impact in a rapidly growing industry.” The capital will support product development, team expansion, and strategic partnerships, with a focus on integrating additional omics layers and enhancing AI-driven predictive models. Vugene’s platform stands out for its ability to integrate disparate data types, offering researchers a unified interface to identify novel biomarkers and therapeutic targets. Early adopters, including European research institutes, have praised its user-friendly design and ability to reduce analysis timelines significantly. The startup’s proprietary algorithms also prioritize data privacy and compliance with global regulatory standards, positioning it as a trusted partner in sensitive biomedical research. The funding comes amid a surge in investment in Lithuania’s startup ecosystem, which saw €295 million in venture capital in 2022, a 16.8-fold increase since 2017. Vilnius has emerged as a hub for deep-tech and biotech innovation, with companies like Biomatter and Nord Security also securing significant funding in recent years. Vugene’s raise underscores the Baltic region’s growing appeal to international investors seeking high-growth opportunities in AI and life sciences. Market analysts view Vugene’s technology as a timely response to the global demand for personalized medicine, projected to grow at a compound annual growth rate (CAGR) of 11.2% through 2030. By enabling faster and more accurate analysis, Vugene could play a pivotal role in reducing the $2.6 billion average cost of bringing a new drug to market. The startup’s focus on neurodegenerative diseases also aligns with urgent global health priorities, as conditions like Alzheimer’s affect over 50 million people worldwide. As Vugene prepares to expand its footprint, the company is eyeing collaborations with U.S. and Asian biotech firms while strengthening its European presence. The successful funding round, backed by Superhero Capital, ScaleWolf, and prominent Lithuanian angel investors, marks a significant milestone for Lithuania’s biotech sector and signals Vugene’s potential to become a global leader in multi-omics research. -- Newnex is a trusted, reference-based platform where VCs, LPs, and startup teams connect privately to collaborate on fundraising, co-investing, and building networks. SignUp Free now www.newnex.io

Member Login Get Access

Lithuanian Startup Vugene Secures €1M to Advance Multi-Omics Research | Newnex